| Company Name: | MZT Holdings | | Ticker Symbol: | MZT | | | WWW Address: | www.matritech.com | | CEO: | Stephen D. Chubb | | No. of Employees: | 75 | | Common Issue Type: | CS | | Business Description: | A biotechnology company, which is engaged in the development, manufacturing, marketing, distribution and licensing of cancer diagnostic technologies and products.
|
| | | Industry Information: | DRUGS - Diagnostic Support [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.092 |  0.0 | - | - | 0 | 0.10 | 0.09 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 5.7 | 62.2 | 0.58 | -0.22 | 0.00 | 0.0 | 0.0 | 0.80 - 0.05 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.09 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 5.7 | mil |
| Latest Shares Outstanding | 62.2 | mil |
| Earnings pS (EPS) | -0.22 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 162,600 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 61.1 | mil |
| Float as % of Shares Outstanding | 98.3 | % |
| Foreign Sales | 8 | mil |
| Domestic Sales | 4 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 114.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 16.40 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | -10.1 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 2.2 | % |
| Return on Assets (ROA) | -236.6 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 160.6 | % |
| Current Ratio | 0.3 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | -0.17 | $ |
| Cash pS | 0.04 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.16 | $ |
| Cash Flow pS | -0.16 | $ |
| Free Cash Flow pS | -0.10 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -0.58 | |
| Price/Cash Flow | -0.6 | |
| Price/Free Cash Flow | -0.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -10.0 | 94 | 1,845 | 9,290 |
| 4 Weeks | 0.12 | 0.05 | 0.09 | 0.0 | 107 | 2,313 | 41,626 |
| 13 Weeks | 0.14 | 0.05 | 0.11 | -18.2 | 90 | 3,213 | 199,223 |
| 26 Weeks | 0.38 | 0.05 | 0.34 | -73.5 | 29 | 2,966 | 373,776 |
| 52 Weeks | 0.80 | 0.05 | 0.67 | -86.6 | 13 | 1,947 | 488,638 |
| YTD | 0.11 | 0.09 | - | -10.0 | 94 | 1,246 | 3,738 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.10 | 0.10 | 0.10 | 0.19 | 0.26 | 0.58 | 0.35 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 35.70 | 95.7 | 24.10 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -8.57 | NA | -15.50 |
| R&D | -5.56 | NA | -2.60 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 24.9 | 40.8 | 17.1 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.04 | -0.03 | -0.01 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | -65.51 |
| Current Ratio | 0.5 |
| Quick Ratio (Acid Test) | 0.4 |
| Liquidity Ratio (Cash) | 0.20 |
| Receivables Turnover | 8.7 |
| Average Collection Period | 41 |
| Working Capital/Equity | 124.4 |
| Working Capital pS | -0.06 |
| Cash-Flow pS | -0.15 |
| Free Cash-Flow pS | -0.12 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -5.98 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 152.7 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | -34.4 |
| LT Debt/Total Liabilities | 1.1 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | -205.84 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 3.44 |
| Tobin's Q Ratio | 1.04 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -2.61 |
| Enterprise Value (EV)/Free Cash Flow | -2.51 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -0.58 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -0.6 |
| Price/Free Cash Flow Ratio - LTM | -0.9 |
| Price/Sales Ratio | 0.40 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.13 |
| Tangible Book Value pS - LTM | -0.16 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | -0.05 |
| Cash pS - LTM | 0.04 |
| Cash Flow pS - LTM | -0.16 |
| Free Cash Flow pS - LTM | -0.10 |
| Earnings pS (EPS) | -0.22 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -53.70 |
| Free Cash Flow Margin 5YEAR AVG | -127.59 |
| Net Profit Margin | -97.9 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -4.20 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | -4.35 |
| Return on Capital Invested (ROCI) | 425.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -385.9 |
| Assets Productivity | 2.20 |
| Return on Assets (ROA) | -216.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -133.0 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 88.0 |
| EBITDA Margin - LTM | -10.1 |
| EBIT Margin - LTM | -52.9 |
| Pre-Tax Profit Margin | -97.9 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | -5,399 |
| Revenue per Employee | 162,600 |
| Net Income per Employee | -159,131 |
| Average Collection Period | 37 |
| Receivables Turnover | 8.7 |
| Day's Inventory Turnover Ratio | -5436 |
| Inventory Turnover | -0.1 |
| Inventory/Sales | 7.9 |
| Accounts Payble/Sales | 10.57 |
| Assets/Revenue | 0.45 |
| Net Working Capital Turnover | -3.38 |
| Fixed Assets Turnover | 7.30 |
| Total Assets Turnover | 2.2 |
| Revenue per $ Cash | 8.35 |
| Revenue per $ Plant | 15.88 |
| Revenue per $ Common Equity | -4.20 |
| Revenue per $ Capital Invested | -4.35 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 116.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 130.4 |
| Research & Devlopment (R&D) as % of Revenue | 23.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 23.5 |
|
|  
|
| |
 |  |